General Trends and Growth Drivers

The ongoing globalization either can develop to the benefit of the emerging Chinese and Indian fine-chemical companies or, if these companies do not succeed in becoming partners of the global life science industry, will allow the top-tier Western companies to maintain their preferred supplier status. 

Industry experts indicate a growth of 6% per year for the fine-chemical industry. This figure is based on an anticipated total revenue growth of 9% per year of the pharmaceutical industry, a third of which results from price 

Fim Chemicals The Industry and the Business, by Peter Poliak Copyright 2007 by John Wiley Sons, Inc. 

New drug launches The new R D technologies adopted by pharma come to fruition and revert the -slump in new product launches Pharma does not succeed in collecting the high-hanging fruit, and more stringent rules (e.g.,economic ones) further hamper new product launches 

Outsourcing policy Pharma abandons chemical manufacture of APIs in -favor of outsourcing Pharma reverts to outsourcing only as last resort in case of capacity constraints or hazardous chemistry 

---